文献速递心境障碍

阿塞那平维持治疗双相I型障碍躁狂或混合发作的随机双盲安慰剂对照试验

Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder.
PubMed 文献 · Am J Psychiatry · 2017-09-26

本试验纳入符合DSM-IV-TR标准的双相I型障碍急性躁狂或混合发作成人患者,先接受12至16周开放标签阿塞那平治疗,达到稳定应答标准者随机进入26周双盲停药期,比较阿塞那平与安慰剂。结果显示阿塞那平组任何心境事件复发时间显著长于安慰剂组,整体耐受性良好。

要点

  • 阿塞那平维持治疗较安慰剂显著延长任何心境事件复发时间。
  • 事后分析中,阿塞那平在躁狂发作和抑郁发作复发时间上均优于安慰剂。
  • 双盲期最常见治疗中出现的不良事件为躁狂和双相I型障碍,安慰剂组发生率高于阿塞那平组。

核心结论

  • 长期阿塞那平治疗在预防双相I型障碍成人心境事件复发方面比安慰剂更有效,且总体耐受性良好。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,包括初始12至16周开放标签期和26周双盲随机停药期。
  • 开放标签期阿塞那平目标剂量为10 mg每日两次,可下调至5 mg每日两次。
  • 完成开放标签期并符合稳定/稳定应答标准的受试者随机接受阿塞那平或安慰剂。
  • 主要疗效终点为双盲期任何心境事件复发时间,采用Kaplan-Meier估计并确定95%置信区间。

主要发现

  • 共549名受试者进入开放标签期,其中253名进入双盲随机停药期(安慰剂组127名,阿塞那平组126名)。
  • 阿塞那平组任何心境发作复发时间较安慰剂组统计学显著延长。
  • 事后分析显示,阿塞那平在躁狂发作和抑郁发作复发时间上均较安慰剂有显著优势。

关键数值与推荐

  • 开放标签期最常见治疗中出现的不良事件为嗜睡(10.0%)、静坐不能(7.7%)和镇静(7.7%)。
  • 双盲期最常见治疗中出现的不良事件为躁狂(安慰剂组11.9%对比阿塞那平组4.0%)和双相I型障碍(6.3%对比1.6%)。

临床怎么用

  • 对于双相I型障碍急性躁狂或混合发作且经阿塞那平治疗达到稳定的成人患者,可考虑以阿塞那平维持治疗以降低心境事件复发风险。
  • 用药期间需关注嗜睡、静坐不能和镇静等不良事件。

局限性

  • 原文摘要未报告双盲期复发时间的具体数值及95%置信区间。
  • 原文摘要未报告随机化后各组基线特征、停药率及统计检验具体P值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The authors determined the efficacy and safety of asenapine in preventing recurrence of any mood episode in adults with bipolar I disorder. METHOD: Adults with an acute manic or mixed episode per DSM-IV-TR criteria were enrolled in this randomized, placebo-controlled trial consisting of an initial 12- to 16-week open-label period and a 26-week double-blind randomized withdrawal period. The target asenapine dosage was 10 mg b.i.d. in the open-label period but could be titrated down to 5 mg b.i.d. After completing the open-label period, subjects meeting stabilization/stable-responder criteria were randomized to asenapine or placebo treatment in the double-blind period. The primary efficacy endpoint was time to recurrence of any mood event during the double-blind period. Kaplan-Meier estimation was performed, and 95% confidence intervals were determined. Safety was assessed throughout. RESULTS: A total of 549 subjects entered the open-label period, of whom 253 enrolled in the double-blind randomized withdrawal period (127 in the placebo group; 126 in the asenapine group). Time to recurrence of any mood episode was statistically significantly longer for asenapine- than placebo-treated subjects. In post hoc analyses, significant differences in favor of asenapine over placebo were seen in time to recurrence of manic and depressive episodes. The most common treatment-emergent adverse events were somnolence (10.0%), akathisia (7.7%), and sedation (7.7%) in the open-label period and mania (11.9% of the placebo group compared with 4.0% of the asenapine group) and bipolar I disorder (6.3% compared with 1.6%) in the double-blind period. CONCLUSIONS: Long-term treatment with asenapine was more effective than placebo in preventing recurrence of mood events in adults with bipolar I disorder and was generally well-tolerated.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Szegedi A, Durgam S, Mackle M, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder. Am J Psychiatry. 2017. PMID: 28946761. doi:10.1176/appi.ajp.2017.16040419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。